RE: In bed with the Gov, newsflow rich. Target: 10 to 30p.2 May 2025 19:30
Peel Hunt will buy newly created shares as market maker and then sell them on in the open market as fast as possible (just like they did in the last two placings)
RE: In bed with the Gov, newsflow rich. Target: 10 to 30p.1 May 2025 11:53
COVID was a different era, when suddenly some firms COULD get full NHS approval for things very quickly as it was a public health emergency. It was very fast paced and exciting, and easy to get carried away.
RE: In bed with the Gov, newsflow rich. Target: 10 to 30p.1 May 2025 11:11
I used to be a bit like Lionel and Amers, until I had a lunch a couple of years ago alongside someone who happens to specialise in market access consulting in the pharma industry. Then the penny really dropped about GDR. At that point I realised that in the UK it was mainly all about NICE and other European countries have the equivalent of their own NICE to go through as well. Really opened my eyes.
No, because they have high cash burn, little revenue, and only a small cash reserve. Plus, not expecting any major news to boost share price until next year.
I haven't owned this for a while. I made a modest profit on various trades previously but sold out completely when it was at about 30pish. They've had other CEs done and some of these products have since been dropped due to lack of commercial success. When the next CE marking is announced, you will notice no change in the share price.
RE: In bed with the Gov, newsflow rich. Target: 10 to 30p.24 Apr 2025 18:39
They currently have about £2.1m given cash burn of £0.5m per month. They will be out of money by end of August, so further fundraise is coming in either June of July at the latest. So you're desperate ramping here isn't going to age well at all.
RE: In bed with the Gov, newsflow rich. Target: 10 to 30p.24 Apr 2025 14:23
Someone would be interested if GDR actually had significant and growing sales. But no one wants to bet on it yet. Perhaps if it secures full NICE funding approval for one of the products that might change though.